MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Johnson & Johnson Gross Profit 2011-2026 | JNJ
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.9 B | 61.4 B | 58.6 B | 13.8 B | 54.2 B | - | 54.6 B | 54.6 B | 50.2 B | 48.6 B | - | 51.6 B | 49.7 B | 44.8 B | 42.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.9 B | 13.8 B | 49.9 B |
Quarterly Gross Profit Johnson & Johnson
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.7 B | 16.1 B | 14.5 B | 15.5 B | 15.6 B | 14.9 B | 14.7 B | 15.1 B | 14.2 B | - | 13.8 B | 16.1 B | 15.8 B | - | 16.1 B | 15.7 B | 15.3 B | - | 14.1 B | 11.8 B | 13.6 B | 13.6 B | 13.9 B | 13.6 B | 13.4 B | 13.4 B | 13.8 B | 13.9 B | 13.4 B | 12.9 B | 12.7 B | 13 B | 12.4 B | 12.1 B | 12.3 B | 13.1 B | 12.2 B | - | 11.9 B | 12.4 B | 12.1 B | 12.4 B | 13.1 B | 13.5 B | 12.7 B | 12.4 B | 12.2 B | 12.4 B | 12 B | 11.6 B | 11.5 B | 11.3 B | 11.2 B | 10.6 B | 10.9 B | 11.4 B | 11.4 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.7 B | 10.6 B | 13.3 B |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Akebia Therapeutics
AKBA
|
190 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B | Britain |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
356 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Aquestive Therapeutics
AQST
|
32.9 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
5.48 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
0.006 | $ 3.13 | -1.26 % | $ 315 M | USA |
 |
Codiak BioSciences
CDAK
|
2.92 K | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | USA |
 |
InflaRx N.V.
IFRX
|
-7.24 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
1.87 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Concert Pharmaceuticals
CNCE
|
7.9 K | - | - | $ 401 M | USA |
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | USA |